Ergomed plc Proposed Board and Management Changes (8274P)
13 February 2019 - 6:00PM
UK Regulatory
TIDMERGO
RNS Number : 8274P
Ergomed plc
13 February 2019
PRESS RELEASE
FOR IMMEDIATE RELEASE
Proposed Board and Management Changes
Guildford, UK - 13 February 2019: Ergomed plc (LSE: ERGO)
('Ergomed' or 'the Company'), a company focused on providing
specialised services to the pharmaceutical industry, announces that
Stuart Jackson, Chief Financial Officer and Board Director has
indicated that he will leave the Company in the Summer of 2019 to
take up a position as Chief Financial Officer of a listed entity,
returning to the energy sector.
Stuart will continue as a Board Director and Chief Financial
Officer of Ergomed PLC until a replacement has been secured in
order to ensure a smooth transition process. A search for his
replacement is underway and the Company will provide an update on
his successor in due course.
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: "I
would like to thank Stuart for his support and contribution to
Ergomed. In the time he has been with us, he has made a positive
impact on the business and has strengthened our finance and
reporting capabilities. I look forward to continuing to work
closely with him over the coming months whilst we select his
successor. We wish Stuart every success in his new role."
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanovic (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGGUAWPUPBPGP
(END) Dow Jones Newswires
February 13, 2019 02:00 ET (07:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024